These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8001283)

  • 21. Circulating tumor cells as biomarkers of head and neck squamous cell carcinoma: an updated view.
    Mangano A; Mangano A; Lianos GD; Levrini L; Picone M; Boni L; Dionigi G
    Future Oncol; 2015; 11(13):1851-3. PubMed ID: 26161921
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of serum tumor markers in head and neck cancer.
    Martin M; Rayo JI; Talavera JR; Muñoz A; Cañizo A
    J Nucl Med Allied Sci; 1990; 34(4 Suppl):235-8. PubMed ID: 2092125
    [No Abstract]   [Full Text] [Related]  

  • 23. Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck.
    Kuropkat C; Lippert BM; Werner JA
    Oncology; 2002; 63(3):280-5. PubMed ID: 12381908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Investigation of the usefulness of CYFRA 21-1 as a tumor marker in squamous cell carcinomas of the head and neck].
    Sano K; Kataoka S; Katoh T; Kawauchi H; Morikawa S
    Nihon Jibiinkoka Gakkai Kaiho; 1997 Jul; 100(7):790-7. PubMed ID: 9277101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours.
    Banal A; Hacene K; Berthelot-Ruff E; Mahé E; Fontana X; Pichon MF
    Tumour Biol; 2001; 22(1):27-35. PubMed ID: 11054024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Role of the tumor marker TAG-72 in head and neck neoplasms].
    Altissimi G; von Garrel C
    HNO; 1990 Oct; 38(10):364-6. PubMed ID: 2283330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum magnesium levels in patients with head and neck cancer.
    Kohli GS; Bhargava A; Goel H; Yadav SP; Saini AS; Singh GP; Lal H
    Magnesium; 1989; 8(2):77-86. PubMed ID: 2755215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can Head and Neck Cancers Be Detected with Mean Platelet Volume?
    Eryilmaz A; Basal Y; Omurlu IK
    Asian Pac J Cancer Prev; 2015; 16(16):7045-7. PubMed ID: 26514488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating tumor-derived DNA may permit the early diagnosis of head and neck squamous cell carcinomas.
    Nunes DN; Kowalski LP; Simpson AJ
    Int J Cancer; 2001 Apr; 92(2):214-9. PubMed ID: 11291048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck.
    Kandiloros D; Eleftheriadou A; Chalastras T; Kyriou L; Yiotakis I; Ferekidis E
    Med Oncol; 2006; 23(4):463-70. PubMed ID: 17303904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A liquid biopsy for head and neck cancers.
    Schmidt H; Kulasinghe A; Perry C; Nelson C; Punyadeera C
    Expert Rev Mol Diagn; 2016; 16(2):165-72. PubMed ID: 26631411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic accuracy of Cyfra 21-1 for head and neck squamous cell carcinoma: a meta-analysis.
    Wang YX; Hu D; Yan X
    Eur Rev Med Pharmacol Sci; 2013 Sep; 17(17):2383-9. PubMed ID: 24065233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of five circulating antigens in patients with head and neck squamous cell carcinoma.
    Screm MC; Grandis S; Cartei G; Cattaruzzi E
    Int J Biol Markers; 1989; 4(1):35-9. PubMed ID: 2501400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma.
    Kuropkat C; Werner JA
    J Laryngol Otol; 2003 Dec; 117(12):1007-8; author reply 1008-9. PubMed ID: 14738621
    [No Abstract]   [Full Text] [Related]  

  • 35. Tumor markers of head and neck carcinoma.
    Eibling DE; Wagner RL; Johnson JT
    Immunol Ser; 1990; 53():357-83. PubMed ID: 2100567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Crystallization test in patients with head and neck neoplasms].
    Kuczkowski J; Zaorski P; Betlejewski A
    Otolaryngol Pol; 1995; 49 Suppl 20():121-4. PubMed ID: 9454116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NFκB-p50 as a blood based protein marker for early diagnosis and prognosis of head and neck squamous cell carcinoma.
    Gupta A; Kumar R; Sahu V; Agnihotri V; Singh AP; Bhasker S; Dey S
    Biochem Biophys Res Commun; 2015 Nov; 467(2):248-53. PubMed ID: 26435503
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnostic value of E-cadherin, MMP-9, activated MMP-13 and anti-p53 antibodies in squamous cell carcinomas of head and neck].
    Al Kassam D; Alvarez Marcos C; Blanco I; de Los Toyos JR; Llorente JL
    Med Clin (Barc); 2007 Dec; 129(20):761-5. PubMed ID: 18093475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum samples should not be used to assess circulating matrix metalloproteinase-9 levels as a prognostic marker of disease.
    Tanus-Santos JE; Gerlach RF
    Int J Cancer; 2006 Feb; 118(3):789; author reply 790. PubMed ID: 16094623
    [No Abstract]   [Full Text] [Related]  

  • 40. The clinical value of serum squamous cell carcinoma antigens 1 and 2 in head and neck squamous cell carcinoma.
    Yasumatsu R; Nakano T; Hashimoto K; Kogo R; Wakasaki T; Nakagawa T
    Auris Nasus Larynx; 2019 Feb; 46(1):135-140. PubMed ID: 30078551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.